Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Other Non-Current Assets (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Other Non-Current Assets for 16 consecutive years, with $61.8 million as the latest value for Q1 2026.

  • Quarterly Other Non-Current Assets rose 5.1% to $61.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $61.8 million through Jan 2026, up 5.1% year-over-year, with the annual reading at $61.8 million for FY2026, 5.1% up from the prior year.
  • Other Non-Current Assets for Q1 2026 was $61.8 million at Usana Health Sciences, up from $59.7 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $62.7 million in Q2 2025, with the low at $51.0 million in Q2 2024.
  • Average Other Non-Current Assets over 5 years is $57.0 million, with a median of $56.5 million recorded in 2023.
  • The sharpest move saw Other Non-Current Assets decreased 9.8% in 2024, then grew 23.0% in 2025.
  • Over 5 years, Other Non-Current Assets stood at $54.8 million in 2022, then increased by 0.18% to $54.9 million in 2023, then grew by 7.13% to $58.8 million in 2024, then rose by 1.54% to $59.7 million in 2025, then rose by 3.51% to $61.8 million in 2026.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $61.8 million, $59.7 million, and $62.7 million for Q1 2026, Q3 2025, and Q2 2025 respectively.